Image Response Assessment Team (IRAT) Shared Resource PROJECT SUMMARY Radiology began as a discipline that specialized in the visualization of anatomy. In the context of cancer, modern technologies and innovations transformed imaging into a non-invasive tool that not only assesses solid tumor size and shape but also interrogates the spatial heterogeneity within tumors on the basis of their radiologic appearance, metabolism, and physiology. The overall goal of the Image Response Assessment Team (IRAT) Shared Resource is to enhance the scientific quality of clinical studies, by offering a single point of entry for Moffitt Cancer Center (MCC) members to access traditional and advanced quantitative image analysis services. To this end, efforts are organized around three Specific Aims, which are to: 1) maintain and improve the high reliability and fast turnaround times for RECIST (Response Evaluation Criteria in Solid Tumors) and other standard tumor assessment metrics; 2) improve therapeutic trials at MCC by translating research advances in radiomics and multi-parameter MRI (mpMRI) analyses into turnkey imaging biomarker services; and 3) provide members with access to non-traditional imaging endpoints for therapeutic trials. IRAT consists of five full-time staff and provides quantitative image-based tumor metrics to support investigator- initiated, cooperative group, and industry-sponsored clinical trials at MCC, and is part of the national consortium of Cancer Center IRATs. IRAT has essential roles in the MCC mission ?to contribute to the prevention and cure of cancer,? by providing the support and services necessary to integrate both traditional and innovative imaging endpoints into clinical trials and by providing quality assurance and control throughout the process to yield scientifically valid results. With rapid advances in treatment paradigms such as immunotherapies, IRAT provides improved imaging endpoints to meet the needs of these cutting-edge studies of MCC members. IRAT has witnessed sustained increases in the volume of quantitative image response assessment services provided. A total of 298 new trials requiring imaging response assessment were activated in FY11-15, rising from 39 in FY11 to 65 in FY15. Developing an infrastructure for IRAT has permitted the pursuit of other funded trial opportunities that use advanced and/or investigational imaging techniques, analyses, and novel biomarkers. For example, IRAT is supporting multiple grant applications and funded projects by members investigating radiomic and mpMRI imaging biomarkers in retrospective and prospective clinical and pre-clinical studies. During the past project period, IRAT served 34 members from 4 MCC Programs. Overall usage by members was 94%, with 63% of total usage supporting members with peer- reviewed funding. IRAT-supported studies resulted in a total of 62 peer-reviewed scientific publications during this period.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA076292-20
Application #
9419799
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-02-01
Budget End
2019-01-31
Support Year
20
Fiscal Year
2018
Total Cost
Indirect Cost
Name
H. Lee Moffitt Cancer Center & Research Institute
Department
Type
DUNS #
139301956
City
Tampa
State
FL
Country
United States
Zip Code
33612
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Lu, Yingchang; Beeghly-Fadiel, Alicia; Wu, Lang et al. (2018) A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Res 78:5419-5430
Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88
Kasting, Monica L; Christy, Shannon M; Sutton, Steven K et al. (2018) Florida physicians' reported use of AFIX-based strategies for human papillomavirus vaccination. Prev Med 116:143-149
Jiang, Kun; Neill, Kevin; Cowden, Daniel et al. (2018) Expression of CAS/CSE1L, the Cellular Apoptosis Susceptibility Protein, Correlates With Neoplastic Progression in Barrett's Esophagus. Appl Immunohistochem Mol Morphol 26:552-556
Park, Jae H; Rivière, Isabelle; Gonen, Mithat et al. (2018) Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia. N Engl J Med 378:449-459
Pamnani, Shitaldas J; Sudenga, Staci L; Rollison, Dana E et al. (2018) Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) Among Men in the HPV Infection in Men (HIM) Study. J Infect Dis 218:1219-1227
Poort, Hanneke; Meade, Cathy D; Knoop, Hans et al. (2018) Adapting an Evidence-Based Intervention to Address Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia Patients. Cancer Nurs 41:E28-E37
Cherezov, Dmitry; Hawkins, Samuel H; Goldgof, Dmitry B et al. (2018) Delta radiomic features improve prediction for lung cancer incidence: A nested case-control analysis of the National Lung Screening Trial. Cancer Med 7:6340-6356
Simmons, Vani N; Sutton, Steven K; Meltzer, Lauren R et al. (2018) Long-term outcomes from a self-help smoking cessation randomized controlled trial. Psychol Addict Behav 32:710-714

Showing the most recent 10 out of 1254 publications